Search Results - "van Kampen, Roel J W"

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome by Lobbezoo, Dorien J. A., van Kampen, Roel J. W., Voogd, Adri C., Dercksen, M. Wouter, van den Berkmortel, Franchette, Smilde, Tineke J., van de Wouw, Agnes J., Peters, Frank P. J., van Riel, Johanna M. G. H., Peters, Natascha A. J. B., de Boer, Maaike, Borm, George F., Tjan-Heijnen, Vivianne C. G.

“…Contrary to the situation in early breast cancer, little is known about the prognostic relevance of the hormone receptor (HR) and human epidermal growth factor…”
Get full text

Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry by VAN KAMPEN, Roel J. W, CANALS, Carmen, MILPIED, Noel J, JOUET, Jean-Pierre, OSSENKOPPELE, Gert J, SUREDA, Anna, SCHOUTEN, Harry C, NAGLER, Arnon, THOMSON, Kirsty J, VERNANT, Jean-Paul, BUZYN, Agnes, BOOGAERTS, Marc A, LUAN, Jian-Jian, MAURY, Sébasticn

“…To analyze the outcome, including nonrelapse mortality (NRM), relapse rate (RR), progression-free survival (PFS), and overall survival (OS), of patients with…”
Get full text

Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia by Thijssen, Rachel, ter Burg, Johanna, Garrick, Brett, van Bochove, Gregor G.W., Brown, Jennifer R., Fernandes, Stacey M., Rodríguez, María Solé, Michot, Jean-Marie, Hallek, Michael, Eichhorst, Barbara, Reinhardt, Hans Christian, Bendell, Johanna, Derks, Ingrid A.M., van Kampen, Roel J.W., Hege, Kristen, Kersten, Marie José, Trowe, Torsten, Filvaroff, Ellen H., Eldering, Eric, Kater, Arnon P.

“…Inhibition of B-cell receptor (BCR) signaling pathways in chronic lymphocytic leukemia (CLL) provides significant clinical benefit to patients, mainly by…”
Get full text

Survey of Challenges, Goals, and Interventions for Patients With Lymphoma During Aftercare Consultation: An Exploratory Cross-Sectional Study by Friesen-Storms, Jolanda HHM, Quadvlieg-Delnoy, Danny JL, van Kampen, Roel JW, van der Weijden, Trudy, Beekman, Emmylou, Bours, Gerrie JJW, Jie, Kon-Siong G

“…This study described the challenges, personal goals, and interventions of patients with lymphoma in various domains of life that emerged from an aftercare…”
Get full text

Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry by Claessens, Anouk K. M., Ramaekers, Bram L. T., Lobbezoo, Dorien J. A., van Kampen, Roel J. W., de Boer, Maaike, van de Wouw, Agnes J., Dercksen, M. Wouter, Geurts, Sandra M. E., Joore, Manuela A., Tjan-Heijnen, Vivianne C. G.

“…Purpose We aimed to evaluate quality of life (QoL) using the European Quality of Life Five-Dimensions questionnaire (EQ-5D-3L) in a real-world cohort of Dutch…”
Get full text

Real‐Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium by Seferina, Shanly C., Lobbezoo, Dorien J.A., Boer, Maaike, Dercksen, M. Wouter, Berkmortel, Franchette, Kampen, Roel J.W., Wouw, Agnès J., Vries, Bart, Joore, Manuela A., Peer, Petronella G.M., Voogd, Adri C., Tjan‐Heijnen, Vivianne C.G.

“…Background. The impact of drug prescriptions in real life as opposed to strict clinical trial prescription is only rarely assessed, although it is well…”
Get full text

Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study by Stege, Claudia A M, Nasserinejad, Kazem, van der Spek, Ellen, Bilgin, Yavuz M, Kentos, Alain, Sohne, Maaike, van Kampen, Roel J W, Ludwig, Inge, Thielen, Noortje, Durdu-Rayman, Nazik, de Graauw, Nicole C H P, van de Donk, Niels W C J, de Waal, Esther G M, Vekemans, Marie-Christiane, Timmers, Gert Jan, van der Klift, Marjolein, Soechit, Savita, Geerts, Paul A F, Silbermann, Matthijs H, Oosterveld, Margriet, Nijhof, Inger S, Sonneveld, Pieter, Klein, Saskia K, Levin, Mark-David, Zweegman, Sonja

“…Frail patients with newly diagnosed multiple myeloma have an inferior outcome, mainly because of a high discontinuation rate due to toxicity. We designed a…”
Get full text

Deferring diagnostic evaluation of suspected deep vein thrombosis using direct oral anticoagulant or low-molecular-weight heparin as a single dose anticoagulant: A prospective real-world study in a regionwide care pathway by Luu, Inge H.Y., Appelboom, Yael, Willems, Jeresa I.A., Gielen, Robbert-Jan C.A.M., Lobbes, Marc B.I., Külcü, Kemal, ten Cate, Hugo, Peeters, Jos, Palmen, Jan, Buijs, Jacqueline, Jie, Kon-Siong G., van Kampen, Roel J.W., Mostard, Guy J.M., van Twist, Daan J.L.

“…Patients with suspected deep vein thrombosis (DVT) are typically referred to the emergency department for immediate evaluation. To enhance efficiency, our…”
Get full text

Cancer-Associated Chemotherapy Induces Less IBD Exacerbations and a Reduction of IBD Medication Afterwards by Koc, Özgür M, van Kampen, Roel J W, van Bodegraven, Adriaan A

“…Abstract Background The prevalence of inflammatory bowel disease (IBD) is increasing and, consequently, more IBD patients will develop cancer with need for…”
Get full text

Deferring diagnostic evaluation for suspected deep venous thrombosis using a single dose of anticoagulant: Real-world data from a regionwide care pathway by Luu, Inge H.Y., Mostard, Guy J.M., van Mil, Dominique, van Berlo, Marlon H.W., Lobbes, Marc B.I., Külcü, Kemal, Cate, Hugo ten, Peeters, Jos, Palmen, Jan, Buijs, Jacqueline, Jie, Kon-Siong G., van Kampen, Roel J.W., van Twist, Daan J.L.

“…•Round-the-clock referrals for workup of suspected DVT can contribute to ED overcrowding.•Deferring workup of suspected DVT with a single dose anticoagulant…”
Get full text

Improving the identification of frail elderly newly diagnosed multiple myeloma patients by Stege, Claudia A. M., Nasserinejad, Kazem, Klein, Saskia K., Timmers, Gert-Jan, Hoogendoorn, Mels, Ypma, Paula F., Nijhof, Inger S., Velders, Gerjo A., Strobbe, Leonie, Durdu-Rayman, Nazik, Westerman, Matthijs, Davidis-van Schoonhoven, Marjan A., van Kampen, Roel J. W., Beeker, Aart, Koster, Ad, Dijk, Amanda C., van de Donk, Niels W. C. J., van der Spek, Ellen, Leys, Rineke B. L., Silbermann, Matthijs H., Groen, Kaz, van der Burg-de Graauw, Nicole C. H. P., Sinnige, Harm A. M., van der Hem, Klaas G., Levenga, Henriette, Bilgin, Yavuz M., Sonneveld, Pieter, Levin, Mark-David, Zweegman, Sonja

Get full text

Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing by van Kuilenburg, André B.P., Meijer, Judith, Maurer, Dirk, Dobritzsch, Doreen, Meinsma, Rutger, Los, Maartje, Knegt, Lia C., Zoetekouw, Lida, Jansen, Rob L.H., Dezentjé, Vincent, van Huis-Tanja, Lieke H., van Kampen, Roel J.W., Hertz, Jens Michael, Hennekam, Raoul C.M.

“…Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5-fluorouracil (5FU). Genetic variations in DPD have emerged…”
Get full text

Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium by Seferina, Shanly C., Boer, Maaike, Derksen, M. Wouter, Berkmortel, Franchette, Kampen, Roel J.W., Wouw, Agnès J., Joore, Manuela, Peer, Petronella G.M., Voogd, Adri C., Tjan‐Heijnen, Vivianne C.G.

“…Introduction. We assessed the incidence and timing of first cardiac events, impact on trastuzumab prescription, and role of left ventricular ejection fraction…”
Get full text

Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium by Seferina, Shanly C, Ramaekers, Bram L T, de Boer, Maaike, Dercksen, M Wouter, van den Berkmortel, Franchette, van Kampen, Roel J W, van de Wouw, Agnès J, Voogd, Adri C, Tjan Heijnen, Vivianne C G, Joore, Manuela A

“…We assessed the real world costs and cost-effectiveness of the addition of trastuzumab in HER2 positive early breast cancer compared to chemotherapy alone in…”
Get full text

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes by Groen, Kazimierz, Smits, Febe, Nasserinejad, Kazem, Levin, Mark‐David, Regelink, Josien C., Timmers, Gert‐Jan, Waal, Esther G. M., Westerman, Matthijs, Velders, Gerjo A., Heer, Koen, Leys, Rineke B. L., Kampen, Roel J. W., Stege, Claudia A. M., Seefat, Maarten R., Nijhof, Inger S., Spek, Ellen, Klein, Saskia K., Donk, Niels W. C. J., Ypma, Paula F., Zweegman, Sonja

Get full text

Bridging Trial and Decision: A Checklist to Frame Health Technology Assessments for Resource Allocation Decisions by Grutters, Janneke P.C., PhD, Seferina, Shanly C., MD, Tjan-Heijnen, Vivianne C.G., MD, PhD, van Kampen, Roel J.W., MD, Goettsch, Wim G., PhD, Joore, Manuela A., PhD

“…Abstract Objective Health technology assessments (HTAs) intend to inform real-world decisions. They often draw on data from explanatory trials and hence are…”
Get full text

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial by Groen, Kaz, Stege, Claudia A.M., Nasserinejad, Kazem, de Heer, Koen, van Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka-Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie-Christiane, Timmers, Gert-Jan, de Boer, Fransien, Tick, Lidwine W., Verbrugge, Annelies, Buitenhuis, Danny, Cunha, Sonia M., van der Spek, Ellen, de Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., van de Donk, Niels W.C.J., Levin, Mark-David, Ypma, Paula F., Zweegman, Sonja

Get full text

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study by Smits, Febe, Groen, Kaz, Levin, Mark-David, Stege, Claudia, Van Kampen, Roel JW, Van Der Spek, Ellen, Bilgin, Yavuz M, Thielen, Noortje, Nijhof, Inger S., Ludwig, Inge, De Waal, Esther G.M., Sandberg, Yorick, Kentos, Alain, Timmers, Gert Jan, Regelink, Josien C, Westerman, Matthijs, de Heer, Koen, Vekemans, Marie Christiane, Durdu-Rayman, Nazik, Graauw, Nicole de, Seefat, Maarten R., van de Donk, Niels WCJ, Ypma, Paula F, Nasserinejad, Kazem, Zweegman, Sonja

“…Introduction The clinical outcome of non-transplant eligible patients with newly diagnosed Multiple Myeloma (NDMM) is heterogeneous, largely depending on…”
Get full text

DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial by de Jonge, A.Vera, Kersten, Marie José, van Werkhoven, Erik, van der Poel, Marjolein, de Heer, Koen, Klerk, Clara, Sandberg, Yorick, Van Rijn, Rozemarijn S, Fijnheer, Rob, Mutsaers, Pim, Vergote, Vibeke, Issa, Djamila, Beeker, Aart, Bilgin, Yavuz M., Böhmer, Lara H., Nieuwenhuizen, Laurens, Stevens, Wendy, van Kampen, Roel JW, Mous, Rogier, Durian, Marc, Snijders, Tjeerd, Vermaat, Joost S.P, Visser, Otto, Zijlstra, Josée M., Hofwegen, Henk, Zanders, Helma G.J.M., Fu, Liping P., De Jong, Daphne, Nijland, Marcel, Chamuleau, Martine E.D.

“…Introduction Patients (pts) with high grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 gene rearrangements (double hit and triple hit (DH/TH)) have…”
Get full text

Cardiotoxicity and cardiac monitoring during adjuvant trastuzumab in daily Dutch practice by Tjan-Heijnen, Vivianne C., Seferina, Shanly C., De Boer, Maaike, van den Berkmortel, Franchette W.P.J., Van Kampen, Roel JW, Van de Wouw, Agnes W, Joore, Manuela A, Borm, George F, Voogd, Adri C

“…Abstract only e11558 Background: In this study we assessed the cardiotoxic effects of adjuvant trastuzumab in daily practice after its introduction in the…”
Get full text